Introduction
Arterial hypertension is the most relevant risk factor for cardiovascular disease worldwide and one of the most common abnormalities identified during clinical evaluation of athletes. 1 The European Society of Cardiology (ESC) guidelines advocate regular physical activity as a Class IA recommendation for the prevention and treatment of cardiovascular disease, 2 which is contributing to the growing number of hypertensive individuals who train regularly and wish to engage in competitive sport. 3 Arterial hypertension has been recognized as a risk factor to coronary artery disease progression and left ventricular (LV) hypertrophy, which represent substrates for myocardial infarction and ventricular arrhythmias. 4 Moreover, arterial hypertension induces structural changes in end-organs including the retina, kidneys, and brain that can lead to injury and increase the risk of spontaneous haemorrhage. 5 Furthermore, an acute increase in blood pressure (BP) during effort may trigger atherosclerotic plaque rupture [6] [7] [8] [9] leading to ischaemic myocardial or cerebrovascular events. 4, [6] [7] [8] [9] Therefore, timely identification of hypertensive individuals is paramount in the setting of pre-participation screening, in order to implement a healthier lifestyle, appropriate management and follow-up. [10] [11] [12] [13] For the purpose of the present position statement, our panel of experts was to propose recommendations, which represent the best possible balance between risks and benefits inherent with competitive sports participation, based on scientific evidence, when available, and consensus of experts. Detailed information on the classification, prevalence, evaluation, and recommendation for patients with arterial hypertension can be found in the current European Society of Hypertension (ESH)/ESC guidelines. 5 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
In this document, competitive athletes are defined as individuals of all ages, who engage in exercise training on a regular basis and participate in official sports competition, be it as amateurs or professionals. 14, 15 Classification Hypertension is defined as systolic BP > _140 mmHg and/or diastolic BP > _90 mmHg ( Table 1) , repeatedly measured in the office. 16 Importantly, children and adolescents have lower BP levels with normal values <120/80 mmHg. 17, 18 In adults, the threshold for an elevated 24 h ambulatory blood pressure monitoring (ABPM) is > _130/80 mmHg (daytime: > _135/85 mmHg; night-time: > _120/ 70 mm Hg). 5, 16, 19 The cuff size should be chosen according to the circumference of the athlete's arm, and in case of asymmetric exercises (e.g. shot put, tennis, etc.) BP can be measured in the non-dominant arm.
Isolated systolic hypertension and isolated diastolic hypertension, both not rare in young men, correspond to an elevated systolic BP with normal diastolic BP or an elevated diastolic BP with normal systolic BP, respectively.
Subjects with elevated BP in the clinic and normal home blood pressure monitoring (HBPM) and/or ABPM have white-coat or isolated clinic hypertension, those with normal office BP but elevated HBPM and/or ABPM have masked hypertension. 20, 21 Also in these conditions, thresholds given above for ABPM and HBPM apply.
During exercise, physiologically systolic BP increases and diastolic BP remains stable or mildly decreases. Even though the association between an exaggerated BP response during exercise testing and cardiovascular events is not well established, it has been related to incident hypertension. 22 Also, 200 mmHg at 100 W has been demonstrated to independently predict long-term mortality in healthy middle-aged men. 23 In Olympic, athletes systolic BP of 220 mmHg in males and 200 mmHg in females measured during cycle ergometry are beyond the 95th percentile 23 and thus warrant further follow-up evaluation including ABPM. 24 
Prevalence
The largest study on arterial hypertension in athletes in Europe (n = 2000; age 25 ± 6 years; 64% males) reported a prevalence of 3% with only a small minority (0.2%) with secondary hypertension. 25 
Evaluation
Assessment of hypertension has to be carried out in the context of other cardiovascular risk factors and resulting target organ damage like cardiovascular and/or renal complications ( Table 2) . 16 Testing for microalbuminuria after 24 h rest 26 and tissue Doppler imaging for plaque detection of carotid arteries may be considered in high-risk subjects. Also, clinical history, assessment of cardiovascular risk, physical examination, and subsequent diagnostic tests should be performed in order to exclude secondary causes, which may account for 5-10%, as they may be reversed with appropriate management. 27 Indeed, widely used supplements, energy drinks, medications (including antiinflammatory drugs or thyroid hormones for weight reduction), or performance enhancing substances (e.g. erythropoietin, anabolic steroids) are an underestimated cause of secondary hypertension. 28, 29 Secondary causes of hypertension should be sought in individuals if:
(1) Age at onset <30 years, (2) Absence of risk factors including family history of hypertension, (3) Grade 3 hypertension (> _180/110 mmHg) or hypertensive emergencies, and (4) Sudden increase in BP in a previously normotensive individual or resistant hypertension despite medical treatment. 27 In case of border line office measurements or in athletes with white-coat or masked hypertension, HBPM and ABPM also during training sessions should be performed.
Echocardiography has its place to assess LV hypertrophy [increased relative wall thickness (RWT) of >0. 42 interventricular septum þ posterior wall/end-diastolic diameter)] and mass (>110 g/m 2 in men, >95 g/m 2 in women), 30 impaired relaxation (measured by tissue Doppler echocardiography) or systolic dysfunction (assessed by longitudinal strain analysis), [31] [32] [33] [34] valves, and the ascending aorta. Long-term, high-volume, and high-intensity endurance sport itself may induce enlargement of all cardiac cavities and mild LV hypertrophy, better known as athlete's heart. Whereas these physiological adaptations are reversible by detraining, 35 remodelling caused by hypertension is not, but is amenable to effective BP lowering therapy.
Exercise testing (with ECG and BP monitoring) 25 should be routinely performed to assess exercise capacity and to rule out exercise-induced hypertension. As stated above, BP values obtained during exercise should not be used for a definitive diagnosis of hypertension, 36 since it is uncertain whether it is a reliable predictor of overt arterial hypertension later in life. 24, [37] [38] [39] Nonetheless, at least annual follow-up preferably with ABPM and particular attention to cardiovascular risk factors is warranted, but without restriction from any competitive sport. 23 
Risk stratification
The terms low-, moderate-, high-, and very high-risk correspond to approximate absolute 10-year risks of cardiovascular mortality of <1%, 1-4%, 5-10%, and >10%, respectively, according to the European SCORE system as defined by the 2016 ESC prevention guidelines. 2 
Recommendations General recommendations
Athletes with hypertension should be treated according to general guidelines. 27 Appropriate non-pharmacological measures should be considered as the first step: salt restriction, weight reduction when obesity is present, alcohol restriction, increased consumption of vegetables and fruits, smoking cessation, discontinuation of supplements, ergogenic, and/or anti-inflammatory drugs. Aerobic-exercise Athletes should be periodically reassessed and in case of low or moderate risk, drug treatment is initiated when hypertension persists, e.g. 3 months after appropriate lifestyle changes have been implemented or when out-of-office BP remains elevated. It is not recommended to initiate antihypertensive therapy at high normal BP, however, lifestyle changes are encouraged. Antihypertensive drug therapy should be started promptly in athletes with Grade 3 hypertension and/or high-or very high risk for cardiovascular complications ( Table 3 ). (Level of evidence: IB).
The goal of antihypertensive therapy is to reduce BP to <140/ 90 mmHg and to <140/85 mmHg in diabetic athletes, 5 although the current trend is to adopt lower values, i.e. <130/80, as recently advocated in the ACC/AHA guidelines. 40 (Level of evidence: IB).
With regard to white-coat or masked hypertension, ABPM may be particularly useful in assessing BP load. With regard to antihypertensive drugs, current evidence indicates that they are not required. In the absence of randomized trials, it will remain an individual decision to prescribe antihypertensive drugs even in patients with high-or very high cardiovascular risk ( Table 3 ). In any case, regular follow-up and non-pharmacological measures are recommended. 27 Also, since it remains uncertain whether isolated systolic or isolated diastolic hypertension progress to overt hypertension or benefit from drug treatment, only lifestyle changes are warranted. (Level of evidence: IB).
Choice of drugs
Athletes who compete at national and/or international level have to review the current list of prohibited substances and methods of the World Anti-Doping Association 41 before starting drug therapy. If required, a therapeutic use exemption has to be obtained in order to receive the authorization to take the needed medicine.
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are the preferred choice as they do not affect exercise capacity and are not on the doping list. However, they shall not be given to females during reproductive years, because of potential adverse foetal/neonatal effects.
Alternatively or additionally calcium channel blockers are a preferred choice in athletes. If more than one drug is required, combination drugs should be considered as they may improve compliance. Beta blockers are rarely used as second line therapy, as they can generally not be given in athletes with bradycardia <50/min and/or second or third degree AV block. Furthermore, different beta blockers (selective/non selective, older/newer compounds, with/without vasodilatory properties) negatively impact aerobic-exercise performance, which may interfere with compliance. Also, beta blockers are prohibited and considered as doping in some sports like archery and shooting where control of tremor is seeked. 16, 42 Diuretics are banned at all times and in all sports, since they may mask performance-enhancing drugs. 43 Figure 2 Classification of different sports disciplines. Sport disciplines are divided according to acute physiologic responses (i.e. heart rate and blood pressure) and long-term impact on cardiac output and remodelling. 45, 46 Skill sports: achievement depends on technical or bodily skill. Increase in heart rate is accompanied by modest increase in blood pressure and cardiac output. No cardiac remodelling. Power sports: achievement depends on explosive muscle power (i.e. high-static exercise). Substantial increase in heart rate and blood pressure during repeated bursts. Cardiac remodelling with increase in left ventricular wall thickness and modest increase in left ventricular cavity size and function occurs. Mixed sports: alternating phases of dynamic and/or static work and recovery (e.g. ball and team sports). Duration and exercise intensity vary largely according to type of sport and the role the athlete plays. Phasic increases in heart rate and blood pressure may reach near-maximum values, alternating with recovery phases. There is cardiac remodelling with increase in left ventricular cavity size and modest change in left ventricular wall thickness. Endurance sports: prolonged and intensive high dynamic, often associated with high-static exercise at near maximal cardiac output, through increase in heart rate, and blood pressure over several hours. Cardiac remodelling with significant increase in left ventricular cavity size and wall thickness is present. -/þ: no, þ: weak, þþ: moderate, and þþþ: strong effect. 
Recommendations for competitive sports participation
Recommendations are based on risk stratification and with the understanding that the clinical condition is stable and that general recommendations for the management of hypertension are observed as described above ( Table 4 ).
1. In patients with low-or moderate-cardiovascular risk, usually no restrictions apply. If BP values are not normalized, temporary restriction from competitive sport is recommended, with possible exception of skill disciplines (Figures 1 and 2) .
2. In patients with high-risk or very high-risk in whom control of BP has been achieved, participation in all competitive sports is possible, with the exception of power disciplines (Figures 1 and 2) . If BP values are not well controlled, temporary restriction from competitive sport is recommended.
Leisure-time and amateur sport activities
Regular exercise training has been shown to reduce morbidity and mortality 47 and is thus a Class IA indication. 2 Patients are advised to perform at least 30 min of moderate-intensity, preferably (but not exclusively) aerobic-exercise training, 5-7 days per week. 5 In patients with low-or moderate cardiovascular risk high-intensity exercises can be performed, 48 even if common but arbitrary cut-offs, e.g. systolic BP > _240 mmHg, are exceeded during peak intervals.
Follow-up
Patients need to be followed up regularly by their physicians. In addition, during annual pre-competition medical examination BP needs to be measured at rest and during exercise testing. Furthermore, possible reversal or progression of existing target organ damage has to be assessed by ECG, echocardiography, kidney testing, and/or retinal examination.
An ACC/AHA statement 9 recommends athletes with hypertension who wish to engage in training for competitive sports to undergo prior clinical assessment including BP, which is in keeping with this position statement and our ESC consensus statement. 49 
Summary
The prevalence of arterial hypertension is high overall, increasing with age and unfavourably influenced by western diet and behaviour even in athletes. Therefore, screening should also focus on adolescent athletes. Special considerations have to be given regarding the pharmacological treatment of hypertension in athletes. While eligibility for competitive sports may have to be restricted if target organ damage is present, an athlete with well-controlled BP, having no additional risk factors or target organ damage, is eligible for competition in all sports.
